Related references
Note: Only part of the references are listed.Non-Criteria Manifestations of Juvenile Antiphospholipid Syndrome
Takako Miyamae et al.
JOURNAL OF CLINICAL MEDICINE (2021)
2019 ESC Guidelines for the dignosis and management of acute pulmonary embolism development Toed in colaboration with the European Respiratory Society (ERS)
Stavros Konstantinides et al.
EUROPEAN HEART JOURNAL (2020)
Direct oral anticoagulants in patients with antiphospholipid syndrome: a cohort study
K. Malec et al.
LUPUS (2020)
British Society for Haematology Guidelines on Investigation and Management of Antiphospholipid syndrome (vol 157, pg 47, 2012)
Deepa R. J. Arachchillage et al.
BRITISH JOURNAL OF HAEMATOLOGY (2020)
Seronegative antiphospholipid syndrome: refining the value of non-criteria antibodies for diagnosis and clinical management
Pasquale Pignatelli et al.
HAEMATOLOGICA (2020)
Venous thromboembolism in adults: summary of updated NICE guidance on diagnosis, management, and thrombophilia testing
Terry McCormack et al.
BMJ-BRITISH MEDICAL JOURNAL (2020)
Is There an Additional Value in Detecting Anticardiolipin and Anti-β2 glycoprotein I IgA Antibodies in the Antiphospholipid Syndrome?
Walid Chayoua et al.
THROMBOSIS AND HAEMOSTASIS (2020)
Use of direct oral anticoagulants in patients with thrombotic antiphospholipid syndrome: Guidance from the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis
Stephane Zuily et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2020)
American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism
Thomas L. Ortel et al.
BLOOD ADVANCES (2020)
Antiphospholipid antibodies and lower extremity peripheral artery disease: A systematic review and meta-analysis
Mira Merashli et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2020)
Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome
Malgorzata M. Bala et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2020)
A single-arm feasibility cohort study of rivaroxaban in antiphospholipid syndrome (vol 6, 52, 2020)
Kimberly Legault et al.
PILOT AND FEASIBILITY STUDIES (2020)
Immunoglobulin G (IgG) anticardiolipin antibodies and recurrent cardiovascular events. A systematic review and Bayesian meta-regression analysis
Daniele Pastori et al.
AUTOIMMUNITY REVIEWS (2019)
EULAR recommendations for the management of antiphospholipid syndrome in adults
Maria G. Tektonidou et al.
ANNALS OF THE RHEUMATIC DISEASES (2019)
Drug levels and bleeding complications in atrial fibrillation patients treated with direct oral anticoagulants
Sophie Testa et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2019)
The Epidemiology of Antiphospholipid Syndrome: A Population-Based Study
Ali Duarte-Garcia et al.
ARTHRITIS & RHEUMATOLOGY (2019)
Relationship of Antiphospholipid Antibodies to Risk of Dementia: A Systematic Review
Tommaso Bucci et al.
JOURNAL OF ALZHEIMERS DISEASE (2019)
Rivaroxaban Versus Vitamin K Antagonist in Antiphospholipid Syndrome A Randomized Noninferiority Trial
Josep Ordi-Ros et al.
ANNALS OF INTERNAL MEDICINE (2019)
Factor Xa inhibitors for preventing recurrent thrombosis in patients with antiphospholipid syndrome: a longitudinal cohort study
T. Sato et al.
LUPUS (2019)
Prevalence of Antiphospholipid Antibodies Negativisation in Patients with Antiphospholipid Syndrome: A Long-Term Follow-Up Multicentre Study
Massimo Radin et al.
THROMBOSIS AND HAEMOSTASIS (2019)
The risk of ischaemic stroke in primary antiphospholipid syndrome patients: a prospective study
M. Radin et al.
EUROPEAN JOURNAL OF NEUROLOGY (2018)
Anticoagulation withdrawal in antiphospholipid syndrome: a retrospective matched-control study
C. M. Yelnik et al.
LUPUS (2018)
Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome
Vittorio Pengo et al.
BLOOD (2018)
Use of direct oral anticoagulants in antiphospholipid syndrome
H. Cohen et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2018)
Low drug levels and thrombotic complications in high-risk atrial fibrillation patients treated with direct oral anticoagulants
S. Testa et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2018)
Increased risk of thrombosis in antiphospholipid syndrome patients treated with direct oral anticoagulants. Results from an international patient-level data meta-analysis
Virginie Dufrost et al.
AUTOIMMUNITY REVIEWS (2018)
Cessation of oral anticoagulants in antiphospholipid syndrome
C. Comarmond et al.
LUPUS (2017)
Direct oral anticoagulants: an alternative treatment for thrombotic antiphospholipid syndrome?
A. S. Resseguier et al.
LUPUS (2017)
The use of direct oral anticoagulants in 56 patients with antiphospholipid syndrome
Katarzyna Malec et al.
THROMBOSIS RESEARCH (2017)
Apixaban for the Secondary Prevention of Thrombosis Among Patients With Antiphospholipid Syndrome: Study Rationale and Design (ASTRO-APS)
Scott C. Woller et al.
CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS (2016)
Antiphospholipid syndrome and anticoagulation quality: a clinical challenge
Daniele Pastori et al.
ATHEROSCLEROSIS (2016)
Direct oral anticoagulants in antiphospholipid syndrome: a real life case series
J. F. Betancur et al.
LUPUS (2016)
Therapy persistence in newly diagnosed non-valvular atrial fibrillation treated with warfarin or NOAC A cohort study
Carlos Martinez et al.
THROMBOSIS AND HAEMOSTASIS (2016)
Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism in the presence of thrombophilia: Findings from RE-COVER®, RE-COVER II, and RE-MEDY™
Samuel Z. Goldhaber et al.
VASCULAR MEDICINE (2016)
Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2/3, non-inferiority trial
Hannah Cohen et al.
Lancet Haematology (2016)
Safety and efficacy of oral direct inhibitors of thrombin and factor Xa in antiphospholipid syndrome
Nicolas Noel et al.
AUTOIMMUNITY REVIEWS (2015)
Patient-level analysis of five international cohorts further confirms the efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies
Laurent Arnaud et al.
AUTOIMMUNITY REVIEWS (2015)
Rivaroxaban use in patients with antiphospholipid syndrome and previous venous thromboembolism
Sciascia Savino et al.
BLOOD COAGULATION & FIBRINOLYSIS (2015)
Non-vitamin K antagonist oral anticoagulants: considerations on once- vs. twice-daily regimens and their potential impact on medication adherence
Bernard Vrijens et al.
EUROPACE (2015)
The use of rivaroxaban in patients with antiphospholipid syndrome: A series of 12 cases
Maksim Son et al.
THROMBOSIS RESEARCH (2015)
The Pathogenesis of the Antiphospholipid Syndrome
Bill Giannakopoulos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study
Vittorio Pengo et al.
BLOOD (2011)
Pathogenesis of antiphospholipid syndrome: understanding the antibodies
Pier Luigi Meroni et al.
NATURE REVIEWS RHEUMATOLOGY (2011)
Increased warfarin consumption and residual fibrin turnover in thrombotic patients with primary antiphospholipid syndrome
Paul R. J. Ames et al.
THROMBOSIS RESEARCH (2011)
Management of antiphospholipid antibody syndrome - A systematic review
W Lim et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)
S Miyakis et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2006)
A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome(WAPS)
G Finazzi et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2005)
Share Paper
